TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Last updated: October 1, 2019
Sponsor: TG Therapeutics, Inc.
Overall Status: Completed

Phase

1

Condition

Colorectal Cancer

Pancreatitis

Infantile Fibrosarcoma

Treatment

N/A

Clinical Study ID

NCT02574663
TGR-1202-102 (RM-404)
  • Ages > 18
  • All Genders

Study Summary

This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically confirmed:

  1. adenocarcinoma of the pancreas (pancreatic cancer)

  2. adenocarcinoma of the colon or rectum (colorectal cancer)

  3. adenocarcinoma of the gastric (gastric cancer)

  4. esophageal cancer

  5. gastrointestinal stromal tumor (GIST)

  • Relapsed or refractory disease

  • Measurable lesion by RECIST 1.1

Exclusion

Exclusion Criteria:

  • Known Hepatitis B, C or HIV infection

  • Previous therapy with any drug that inhibits the PI3K pathway

  • Anti-tumor therapy within 21 days of study Day 1

Study Design

Total Participants: 66
Study Start date:
September 11, 2015
Estimated Completion Date:
August 31, 2018

Study Description

TGR-1202 will be evaluated alone or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with adenocarcinoma of the pancreas, adenocarcinoma of the colon, rectum, gastric and GE junction cancer, and GI Stromal Tumor (GIST) who have relapsed from or are refractory to prior treatment.

Connect with a study center

  • TG Therapeutics Trial Site

    Nashville, Tennessee 37203
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.